Get the Stockscreener App
40.62
5.37%
2.07
After Hours:
41.38
0.76
+1.87%
Guardant Health Inc stock is traded at $40.62, with a volume of 2.50M.
It is up +5.37% in the last 24 hours and down -14.00% over the past month.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$38.55
Open:
$38.31
24h Volume:
2.50M
Relative Volume:
1.20
Market Cap:
$5.03B
Revenue:
$692.26M
Net Income/Loss:
$-512.41M
P/E Ratio:
-9.5802
EPS:
-4.24
Net Cash Flow:
$-274.36M
1W Performance:
+6.89%
1M Performance:
-14.00%
6M Performance:
+14.07%
1Y Performance:
+47.87%
1-Day Range:
$38.07
$41.15
1-Week Range:
$37.73
$41.15
52-Week Range:
$20.14
$52.92
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
40.62 | 4.59B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
402.82 | 151.18B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.90 | 134.17B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
513.36 | 40.60B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
111.92 | 31.27B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
140.33 | 23.88B | 15.50B | 1.33B | 2.16B | 7.34 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Upcoming Chicago Meeting for Guardant Health (GH) Investors | GH Stock News - GuruFocus
Guardant Health Inc (GH) Stock Price Up 5.11% on May 30 - GuruFocus
How Delfi Therapeutics plans to make liquid biopsies more accessible - The Business Journals
Guardant Health, Inc. (GH) Expands Liquid Biopsy to Pinpoint Tumor Origins and Biomarkers - MSN
Guardant Health Inc (GH) Trading Down 3.27% on May 28 - GuruFocus
Firing on All Cylinders: Guardant Health (NASDAQ:GH) Q1 Earnings Lead the Way - Yahoo Finance
Guardant Health enhances cancer blood test capabilities By Investing.com - Investing.com Nigeria
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test | GH Stock News - GuruFocus
Guardant Health enhances cancer blood test capabilities - Investing.com
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test - Eagle-Tribune
New Tests Promise to Reveal the Secrets in Your Blood - WSJ
Investor Attention Turns to Biotech as Traditional Cancer Research Models Strain - Baystreet.ca
Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting - BioSpace
(GH) Technical Data - news.stocktradersdaily.com
Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting | GH Stock News - GuruFocus
Guardant Health, Evolent Health, Charles River Laboratories, Avantor, and Lumen Stocks Trade Down, What You Need To Know - Yahoo Finance
Guardant Health (GH) introduces IHC Solid Tumor Testing to its Portfolio - Insider Monkey
Guardant Health Launches Immunohistochemistry Testing for Solid Tumors - marketscreener.com
Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors - BioSpace
Guardant Health, Inc. Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors - marketscreener.com
Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors | GH Stock News - GuruFocus
Guardant Health expands oncology testing with IHC suite - Investing.com
Guardant Health unveils new cancer risk test By Investing.com - Investing.com South Africa
Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer - BioSpace
Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer | GH Stock News - GuruFocus
Guardant Health unveils new cancer risk test - Investing.com
Guardant Health: A Promising Player in the Liquid Biopsy Market - The Globe and Mail
Guardant Health: A Promising Player In The Liquid Biopsy Market - Barchart.com
New Horizons in Cancer Genetic Profiling Market Exploring - openPR.com
Guardant Health, Inc. (NASDAQ:GH) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Transcript : Guardant Health, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03 - marketscreener.com
GH Q1 Earnings Call: Guardant Health Lifts Full-Year Guidance Following Oncology and Screening Momentum - Yahoo Finance
How to Take Advantage of moves in (GH) - news.stocktradersdaily.com
Guardant Health to Participate in Upcoming Investor ConferencesMay 8, 2025 - BioSpace
TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year - 01net
TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List o - GuruFocus
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - BioSpace
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GH Stock News - GuruFocus
Guardant Health (GH) Price Target Raised by Piper Sandler to $60 - GuruFocus
Guardant Health (GH) Price Target Raised by Piper Sandler to $60 | GH Stock News - GuruFocus
Piper Sandler Boosts Guardant Health (GH) Price Target to $60 | - GuruFocus
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Guardant Health Inc Stock (GH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tariq Musa | Director |
May 15 '25 |
Option Exercise |
0.00 |
250 |
0 |
3,595 |
| POTTER MYRTLE S | Director |
May 15 '25 |
Option Exercise |
0.00 |
68 |
0 |
14,063 |
| EAGLE CRAIG | Chief Medical Officer |
May 15 '25 |
Option Exercise |
0.00 |
3,718 |
0 |
36,318 |
| Chudova Darya | Chief Technology Officer |
May 15 '25 |
Option Exercise |
0.00 |
8,705 |
0 |
83,210 |
0.78%
1.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):